UCB Pipeline

Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.

Dapirolizumab pegol is being co-developed with Biogen. 1st phase 3 study.

STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine, that has the potential to be the first rescue treatment to be administered by a patient or caregiver in an out-patient setting to rapidly terminate (within 90 seconds) an ongoing seizure.

Rezanecel is an investigational allogenic regenerative GABA interneuron cell therapy, administered in a one-time, minimally invasive delivery procedure designed to integrate into dysregulated neural circuits and restore inhibitory tone

Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.

Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator. This orally available, brain-penetrant, small molecule is designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control. It is being studied for the treatment of Parkinson's disease.
 

Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways.   It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.
 

Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways.   It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways.   It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing plasma cells and B-cells